Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

20.84 -0.07 (-0.33%)
Delayed Quote Updated: 1:52 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy ↗
The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE: 
Via Benzinga
News headline image
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
3 Promising Biotech Stocks Flying Under the Radar ↗
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
News headline image
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Looking Into Takeda Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 26, 2023 ↗
Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion. 
Via Benzinga
News headline image
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗
Analysts say Alkermes' drug is clearly active. But investors have concerns. 
Via Investor's Business Daily
News headline image
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin... 
Via Talk Markets
News headline image
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners ↗
Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF). 
Via Benzinga
News headline image
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Takeda Withdraws Lung Cancer Drug From US After Failed Confirmatory Trial ↗
Following discussions with the FDA, Takeda Pharmaceutical Co Ltd (NYSE: TAK) will voluntarily withdraw Exkivity (mobocertinib)  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Takeda Provides Update on EXKIVITY® (mobocertinib)
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Can Japan's Economy Continue To Blossom If Bank of Japan Raises Rates? Apparently So. ↗
Amid an economic climate of high interest rates in the US and a slumber among China stocks led by a downturn in the property market, Japan’s economy lies in stark contrast to the antipathy that... 
Via Benzinga
Topics Economy
News headline image
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — 
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Morphic Therapeutic's Stock Plunges On Monday - Here's Why? ↗
Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results... 
Via Benzinga
News headline image
The Surprise That Prompted Morphic Therapeutic To Dump 52% Over Two Days ↗
The company is working on a treatment for ulcerative colitis. But competitive questions linger. 
Via Investor's Business Daily
News headline image
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Top 4 Health Care Stocks That Should Keep You Up At Night ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.